Discover 3,564 paid clinical trials in Long Beach, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,564
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: Irvine CA, Duarte CA, Phoenix AZ, Grand Junction CO,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT06686771
Phase3, Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Los Angeles CA, Irvine CA, Duarte CA, Phoenix AZ,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07258511
Phase3, Recruiting
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
for
Duchenne Muscular Dystrophy
Location: Los Angeles CA, La Jolla CA, Palo Alto CA,
Sponsor: Sarepta Therapeutics, Inc.
Sex: Male
Age: 2+
Code: NCT04626674
Phase1, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
for
Solid Tumors Harboring MET Amplification
Location: Beverly Hills CA, Los Angeles CA, Duarte CA,
Sponsor: AbbVie
Sex: All
Age: 12+
Code: NCT07196644
Phase2, Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
for
Non-alcoholic Fatty Liver Disease
Location: Los Angeles CA, Covina CA, Arcadia CA, Van Nuys CA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70+
Code: NCT07221188
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC